PTC Therapeutics (PTCT) stock price, revenue, and financials

PTC Therapeutics market cap is $4.7 b, and annual revenue was $306.98 m in FY 2019

$4.7 B

PTCT Mkt cap, 15-Jan-2021

$118.4 M

PTC Therapeutics Revenue Q3, 2020
PTC Therapeutics Net income (Q3, 2020)-69.7 M
PTC Therapeutics EBIT (Q3, 2020)-55.1 M
PTC Therapeutics Cash, 30-Sept-2020434 M
PTC Therapeutics EV4.7 B

PTC Therapeutics Income Statement

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

6.9m16.3m9.2m1.7m1.7m7.5m6.8m9.8m18.9m15.6m23.0m26.5m48.0m41.9m56.1m68.7m53.6m53.6m85.5m71.4m68.3m75.2m118.4m

Cost of goods sold

39.0k758.0k1.6m3.0m2.6m3.3m2.4m3.2m3.0m

Gross profit

26.5m47.2m40.3m53.0m66.2m50.3m51.2m82.3m68.4m

Gross profit Margin, %

100%98%96%95%96%94%96%96%96%

R&D expense

14.7m13.9m15.9m18.3m18.8m27.9m28.2m30.6m31.4m28.8m31.4m27.4m30.8m30.0m31.4m32.6m54.4m52.6m60.0m63.1m90.1m93.0m

General and administrative expense

6.6m6.7m7.5m8.7m10.5m17.6m17.2m21.4m25.9m23.4m23.7m25.5m28.9m31.4m33.0m33.5m38.4m40.5m49.2m49.3m58.2m57.8m

Operating expense total

21.3m20.6m23.4m27.0m29.3m45.6m45.4m52.0m57.3m52.2m55.1m52.9m59.7m71.2m69.8m71.7m98.5m120.3m121.1m128.9m148.3m150.8m

Depreciation and amortization

9.7m5.4m5.6m5.8m7.0m7.9m9.6m

EBIT

(14.5m)(4.3m)(14.2m)(25.4m)(27.6m)(38.1m)(38.6m)(42.2m)(38.4m)(36.6m)(32.1m)(26.4m)(12.5m)(30.9m)(16.7m)(5.6m)(48.2m)(69.1m)(38.8m)(60.5m)(93.0m)(55.1m)

EBIT margin, %

(211%)(26%)(154%)(1513%)(1629%)(509%)(570%)(432%)(203%)(234%)(139%)(99%)(26%)(74%)(30%)(8%)(90%)(129%)(45%)(85%)(136%)(47%)

Interest expense

114.2k26.7k171.0k248.0k354.0k524.0k498.0k852.0k2.0m2.1m2.1m2.2m3.0m3.4m3.3m2.9m3.1m2.3m2.1m2.7m5.6m21.0m

Pre tax profit

(38.2m)(43.1m)(41.1m)(39.0m)(35.0m)(28.9m)(17.3m)(33.5m)(19.0m)(9.1m)(50.6m)(71.5m)(41.0m)(60.3m)(112.5m)(47.4m)

Income tax expense

145.0k88.0k114.0k(93.0k)184.0k165.0k150.0k191.0k221.0k389.0k355.0k(576.0k)774.0k(344.0k)222.0k22.3m

Net Income

(14.6m)(4.4m)(14.1m)(25.1m)(27.3m)(37.9m)(38.4m)(43.2m)(41.2m)(38.9m)(35.2m)(29.1m)(17.5m)(33.7m)(19.3m)(9.5m)(51.0m)(72.1m)(41.8m)(60.0m)(112.7m)(69.7m)

PTC Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

15.4m49.7m58.0m58.3m111.8m169.5m288.0m

Accounts Receivable

4.4m11.1m24.9m40.4m67.9m55.5m

Prepaid Expenses

1.6m3.9m5.9m6.7m9.2m17.9m

Inventories

4.7m10.8m16.1m19.3m

Current Assets

145.0m323.6m355.9m261.3m249.1m320.9m779.3m

PP&E

6.7m9.2m9.0m8.4m12.7m21.5m

Goodwill

82.3m82.3m

Total Assets

151.9m333.2m368.0m269.3m391.7m1.1b1.6b

Accounts Payable

1.1m4.1m11.9m48.8m15.3m6.0m10.3m

Short-term debt

48.6k11.7m20.0m

Current Liabilities

13.1m32.5m45.4m49.6m82.0m166.8m235.9m

Long-term debt

94.6m98.2m145.0m141.3m293.9m

Total Debt

48.6k94.6m98.2m145.0m153.0m313.9m

Total Liabilities

15.4m34.8m142.0m149.8m235.2m768.5m1.0b

Common Stock

24.3k33.0k34.0k42.0k51.0k62.0k

Additional Paid-in Capital

465.2m721.7m820.2m856.1m966.5m1.3b1.8b

Retained Earnings

(328.8m)(422.6m)(593.0m)(735.1m)(814.1m)(938.9m)(1.2b)

Total Equity

136.5m298.5m226.0m119.6m156.4m350.7m594.3m

Debt to Equity Ratio

0 x0.4 x0.8 x0.9 x0.4 x

Debt to Assets Ratio

0 x0.3 x0.4 x0.4 x0.1 x

Financial Leverage

1.1 x1.1 x1.6 x2.3 x2.5 x3.2 x2.7 x

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

154.1m24.0m115.9m21.2m52.9m36.8m29.2m140.7m40.2m35.7m50.3m54.1m133.0m141.8m97.7m223.8m206.9m201.1m136.1m523.6m123.3m158.5m434.0m

Accounts Receivable

1.3m3.2m5.1m8.0m22.6m19.8m27.4m32.2m33.8m38.7m45.6m59.4m42.2m46.4m77.1m60.4m52.6m53.6m56.8m

Prepaid Expenses

1.6m2.1m2.0m2.6m2.8m6.1m4.2m4.6m5.1m4.8m4.9m4.6m5.2m5.4m5.8m6.3m8.0m9.3m17.4m20.7m24.3m34.1m26.9m

Inventories

1.4m6.9m7.8m12.4m13.9m13.7m16.2m16.9m17.1m19.1m18.4m19.5m

Current Assets

168.2m160.1m249.4m230.3m213.5m289.8m264.6m384.2m326.4m297.4m280.6m240.7m227.0m221.3m242.0m375.6m313.3m479.1m475.0m806.9m691.9m605.0m1.2b

PP&E

7.2m6.9m6.3m6.4m6.2m9.4m9.0m8.8m8.4m7.6m7.1m7.1m6.8m6.9m8.3m8.2m8.8m14.5m15.4m18.5m26.2m26.8m28.1m

Goodwill

100.3m82.3m82.3m82.3m82.3m

Total Assets

175.5m167.2m255.8m237.6m220.8m299.5m273.8m396.1m335.2m305.6m288.2m248.6m383.1m367.7m379.4m511.8m1.0b1.3b1.3b1.6b1.5b1.5b2.2b

Accounts Payable

425.4k1.0m387.0k613.0k518.0k3.1m3.4m8.7m16.0m16.8m19.2m3.6m6.1m6.0m3.1m4.4m6.5m9.8m10.2m9.0m16.1m15.5m15.7m

Short-term debt

2.7m84.2k12.0k1.7m6.7m16.7m20.0m20.0m20.0m23.2m5.9m

Current Liabilities

19.8m13.9m9.2m11.6m17.3m23.9m23.1m31.7m43.9m42.9m48.9m45.4m68.0m71.9m72.7m86.5m114.9m143.0m174.0m183.5m217.7m201.8m253.8m

Long-term debt

93.2m93.4m94.9m96.6m99.9m141.2m143.1m146.9m147.2m144.3m147.2m144.1m302.6m294.6m319.1m407.3m

Total Debt

2.7m84.2k12.0k93.2m93.4m94.9m96.6m99.9m141.2m143.1m146.9m148.9m150.9m155.1m164.1m322.6m314.6m342.3m413.1m

Total Liabilities

22.5m16.2m11.5m13.8m19.5m26.2m25.2m126.9m139.2m139.9m148.0m147.8m213.3m221.8m229.1m244.4m642.5m771.0m802.9m977.8m1.0b904.1m1.7b

Common Stock

24.3k24.3k30.0k30.0k30.0k33.0k34.0k34.0k34.0k34.0k34.0k34.0k41.0k41.0k42.0k47.0k51.0k58.0k58.0k61.0k62.0k67.0k68.0k

Additional Paid-in Capital

459.4m462.0m587.1m591.6m596.6m734.5m747.9m812.3m829.1m837.9m847.7m865.8m949.3m958.2m975.4m1.1b1.3b1.5b1.5b1.8b1.8b2.1b2.1b

Retained Earnings

(306.5m)(310.9m)(342.9m)(368.0m)(395.3m)(460.5m)(498.8m)(542.0m)(634.2m)(673.1m)(708.3m)(764.2m)(781.6m)(815.4m)(830.1m)(839.6m)(890.6m)(1.0b)(1.1b)(1.1b)(1.3b)(1.5b)(1.6b)

Total Equity

152.9m151.0m244.3m223.8m201.3m273.3m248.6m269.2m196.0m165.6m756.0k(876.0k)2.0m3.0m150.3m267.4m386.1m512.9m488.7m663.7m528.7m572.5m511.0m

Debt to Equity Ratio

0 x0 x0.3 x0.5 x0.6 x127.7 x-114 x70.7 x47.5 x1 x0.6 x0.4 x0.3 x

Debt to Assets Ratio

0 x0 x0.2 x0.3 x0.3 x0.3 x0.4 x0.4 x0.4 x0.4 x0.3 x0.1 x0.1 x

Financial Leverage

1.1 x1.1 x1 x1.1 x1.1 x1.1 x1.1 x1.5 x1.7 x1.8 x381.2 x-283.8 x191.6 x122 x2.5 x1.9 x2.7 x2.5 x2.6 x2.5 x2.9 x2.6 x4.3 x

PTC Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(51.6m)(93.8m)(170.4m)(142.1m)(79.0m)(128.1m)(251.6m)

Depreciation and Amortization

2.4m2.2m2.9m3.3m17.7m26.1m32.2m

Accounts Receivable

56.1k(3.5m)(6.9m)(14.8m)(12.2m)(29.6m)11.5m

Inventories

(6.5m)(5.8m)(3.5m)

Accounts Payable

5.2m16.9m17.0m4.3m24.0m43.9m26.8m

Cash From Operating Activities

(46.9m)(57.3m)(124.3m)(103.6m)(10.1m)(27.6m)(98.6m)

Purchases of PP&E

(845.7k)(4.7m)(2.7m)(1.8m)(3.1m)(7.1m)(13.8m)

Cash From Investing Activities

(127.8m)(145.2m)(20.8m)104.5m13.1m(42.6m)(387.2m)

Long-term Borrowings

(5.0m)(49.0k)

Cash From Financing Activities

187.4m237.1m154.1m968.0k44.2m131.6m613.2m

Net Change in Cash

12.7m34.3m8.3m299.0k53.5m57.7m126.0m

Interest Paid

367.1k1.0k4.5m6.3m7.8m7.7m

Income Taxes Paid

2.1k111.0k943.0k1.1m1.6m2.1m

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(29.3m)(33.7m)(14.1m)(39.2m)(66.5m)(37.9m)(76.3m)(119.5m)(41.2m)(80.1m)(115.3m)(29.1m)(46.5m)(80.3m)(19.3m)(28.8m)(79.8m)(72.1m)(113.9m)(173.9m)(112.7m)(294.1m)(363.8m)

Depreciation and Amortization

1.2m1.8m588.0k1.2m1.7m634.0k1.3m2.1m849.0k1.7m2.5m612.0k1.4m11.7m6.0m12.2m19.3m7.1m14.8m22.9m9.2m19.4m31.1m

Accounts Receivable

143.2k230.0k120.0k100.0k(338.0k)1.3m(669.0k)(3.6m)(10.7m)(8.5m)(16.0m)(6.7m)(6.8m)(11.0m)(4.2m)(20.4m)(2.7m)20.8m(9.7m)5.9m2.3m1.9m121.0k

Inventories

(1.3m)(2.8m)(3.6m)(1.4m)(3.4m)(3.3m)(334.0k)(852.0k)(1.6m)102.0k943.0k390.0k

Accounts Payable

3.0m3.2m(3.5m)(866.0k)4.3m(5.6m)(6.0m)2.9m(2.5m)(3.4m)2.1m(3.9m)12.5m11.8m(6.8m)2.2m18.6m(28.7m)(7.5m)695.0k(4.0m)(7.5m)54.4m

Cash From Operating Activities

(27.3m)(32.5m)(13.4m)(32.2m)(49.3m)(36.4m)(66.2m)(94.0m)(41.6m)(66.2m)(90.2m)(28.9m)(15.6m)(31.4m)(15.9m)(15.9m)(12.5m)(42.4m)(72.9m)(88.4m)(81.6m)(156.4m)(129.7m)

Purchases of PP&E

(95.8k)(473.8k)(186.0k)(837.0k)(1.2m)(883.0k)(1.2m)(1.8m)(265.0k)(275.0k)(540.0k)(225.0k)(579.0k)(1.1m)(479.0k)(1.2m)(2.5m)(2.9m)(4.9m)(9.1m)(6.0m)(8.2m)(11.5m)

Cash From Investing Activities

(11.7m)(133.7m)(4.3m)(80.4m)(32.0m)20.6m37.3m31.0m22.1m43.1m81.4m24.4m47.9m67.2m(1.6m)6.1m(18.0m)(150.5m)(188.7m)(158.2m)(101.3m)40.8m(353.4m)

Long-term Borrowings

(2.2m)(5.0m)(37.0k)(49.0k)(49.0k)(5.0m)(25.0m)(46.2m)

Cash From Financing Activities

190.3m187.5m118.1m118.4m118.7m3.0m8.1m154.0m34.0k34.0k926.0k663.0k40.7m42.4m1.1m122.8m127.8m225.7m228.6m610.9m18.5m(14.4m)628.6m

Net Change in Cash

151.4m21.3m100.4m5.8m37.5m(12.9m)(20.5m)91.0m(17.9m)(22.4m)(7.7m)(4.2m)74.7m83.5m(14.1m)112.0m95.1m31.6m(33.4m)361.6m(164.7m)(129.6m)145.9m

Interest Paid

282.5k365.6k1.0k1.0k1.0k2.3m2.3m4.5m2.3m2.5m5.5m3.0m3.8m6.9m3.1m3.1m7.0m4.9m5.3m9.8m

Income Taxes Paid

225.0k264.0k633.0k28.0k334.0k616.0k326.0k758.0k919.0k537.0k1.0m1.9m507.0k1.1m1.6m

PTC Therapeutics Ratios

USDQ2, 2013

Financial Leverage

1.1 x

PTC Therapeutics Employee Rating

353 votes
Culture & Values
3.1
Work/Life Balance
2.7
Senior Management
2.7
Salary & Benefits
3.9
Career Opportunities
3
Source